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Background
DMF is recommendedas a first-tier treatment in patients with RRMS. Since the implementation 
of DMF in RRMS, five cases of Progressive Multifocal Leukoencephalopathy (PML) have been 
reported in DMF treated MS. None of these patients had previously received immunomodulatory 
therapy. According to EMA guidelines treatment with DMF should be discontinued in severe 
lymphopenia when lymphocyte count drops below 0.5x109/L [1]. DMF may be administered to 
other patients with autoimmune disease, such as psoriasis (Fumaderm) and ongoing clinical trials 
study its effect in patients with T cell lymphoma the exact mode of action of DMF is not clear, 
however, experimental data highlight its role in inhibiting the NF-κβ signalling pathway leading to 
T cell apoptosis in subsets of T cells [2].
Case Presentation
We report a 65 year-old woman diagnosed with RRMS in 1995 presenting with aleft optic 
neuritis followed by a right optic neuritis in 2003. Her last clinical attack was reported in 2009 with 
a left leg paresis. From time of diagnosis to admission in our department she demonstrated only a 
slight progression in EDSS from initially 3 to 4. Follow-up brain MRI, however, was suggestive of 
possible radiographic disease activity and the patient was switched from glatiramer acetate treatment 
to DMF in 2014. Clinically, she presented with visual impairment and she was able to swim, walk 5 
kilometres and required no assistance in walking or activities of daily living.Co-morbidities included 
hypertension, diabetes mellitus, glaucoma and a previous occipital stroke.
Lymphocyte blood counts were performed prior to initiation of DMF and were all within 
normal range (baseline white blood cells 7,3x109/L, lymphocytes 2,1x109/L). After 6 months of 
treatment she developed protracted lymphopenia with counts dropping to 0.7x109/L which further 
decreased to 0.5x109/L at 9 month follow-up. DMF dose was lowered to half the dose. In spite of 
this, lymphopenia dropped to 0.36x109/L and DMF was discontinued after 18 months of treatment.
One month after cessation of DMF the patient was still lymphopenic and admitted to our 
department in prolonged status epilepticus. Neurological exam demonstrated near blindness, 
slurred speech, confusional state and decreased level of consciousness. Moreover, she had a fever 
(39.20 C). A brain CT scan was without any acute changes. Blood counts revealed leucocytes of 
14.1x109/L and lymphocytes of 0.30x109/L. Lumbar puncture demonstrated severe polymorphic 
leucocytosis with 584x106 cells/L. Treatment for bacterial meningoencephalitis concurrent with 
acyclovir was initiated. A control MRI was performed and demonstrated acute hyperintense 
changes in the left insula, thalamus and hippocampus consistent with encephalitic changes. Despite 
prompt microbial therapy, the patient developed respiratory failure and was admitted to the ICU 
for 3 weeks. Continued EEG monitoring revealed paroxysmal focal activity from the left occipito-
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Abstract
Short summary: We report an incidence of bacterial meningoencephalitis with an otherwise low-virulent 
infectious agent, following monotherapy with dimethylfumarate (DMF) in an elderly woman with Relapsing 
Remitting Multiple Sclerosis (RRMS). DMF was first lowered to half the dose and eventually discontinued due to 
persistent lymphopenia. 
A well known side effect of DMF is lymphopenia. In elderly patients DMF induced lymphopenia may provoke 
severe infection with otherwise ubiquitous low-virulent agents. We recommend caution when prescribing DMF 
to elderly RRMS patients in case of lymphopenia and discontinuation may need to be considered even at mild-
moderate lymphopenia in elderly RRMS patients.
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parieto-temporal region. Extensive infectious work-up including 
JC virus were all negative except from a positive 16S rRNAPCR for 
Chryseobacterium in the spinal fluid. The patient was discharged 
from the hospital no longer able tocare for herself independently 
and was subsequently readmitted four times with prolonged status 
epilepticus prior to final dismission to a nursing home.
Discussion
Chryseobacterium is a ubiquitous bacterium found in soil 
and plants and has been associated with meningoencephalitis in 
immunocompromised adults [3,4]. In a study by AH Cross et al., [5] 
of 144DMF treated patients 14% of the patients developed grade 2 
or 3 lymphopenia. The risk of severe lymphopenia was significantly 
higher at ≥55 years of age. Despite normal baseline lymphocyte 
count, no prior treatment with natalizumab or concurrent treatment 
with immunosuppressive or immunomodulatory drugs, our 
patient developed severe prolonged lymphopenia and subsequently 
meningoencephalitis not related to JC virus. It remains plausible 
that the severe lymphopenia secondary to DMF treatment rendered 
the patient susceptible to meningoencephalitis by an otherwise low 
pathogenic environmental agent, chryseobacterium. Moreover, 
higher age could be a possible risk factor of lymphopenia in DMF 
treatment, which may be associated with an increased risk of 
opportunistic infections. 
Conclusions
Current EMA guidelines and national guidelines recommend 
discontinuation of DMF when lymphocyte count drops below 
0.5x109/L. Since the occurrence of a fifth case of PML in DMF 
treated MS patients, updated guidelines recommends risk-benefit 
stratification in DMF associated lymphopenia. Serial measurements 
revealing continuous lymphocyte counts between 0.8x109/L-0.5x109/L 
should prompt consideration of testing JC virus seropositivity. This 
case report highlight the need for risk-benefit stratification in patients 
≥55 years of age, even in patients with normal baseline lymphocyte 
counts. When elderly patients develop lymphopenia due to DMF we 
suggest considering discontinuation rather than lowering the dose. 
This case report, to the best of our knowledge, is the first report of 
severe meningoencephalitis due to chryseobacterium in an adult 
MS patient treated with DMF. This case report further highlights 
that DMF induced lymphopenia mimics an immunocompromised 
state, especially in elderly MS patients, which may increase the risk of 
serious brain infections completely unrelated to JC virus status.
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